{"doi":"10.1016/j.lungcan.2022.10.006","title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial","abstract":null,"journal":"Lung Cancer","year":2022,"id":611599,"datarank":0.5289540786924243,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"self_citation_contribution":0.5289540786924243,"citation_network_contribution":0.0,"self_endowment_contribution":0.5289540786924243,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":33,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":574716,"name":"Luyang Yao","orcid":"0009-0005-3917-0749","position":1,"is_corresponding":false},{"id":274146,"name":"Neda Kalhor","orcid":"0000-0001-6891-6435","position":2,"is_corresponding":false},{"id":345566,"name":"Brett W. Carter","orcid":"0000-0002-3841-8352","position":3,"is_corresponding":false},{"id":236012,"name":"Mehmet Altan","orcid":"0000-0001-9229-156X","position":4,"is_corresponding":false},{"id":1017059,"name":"George Blumenschein","orcid":null,"position":5,"is_corresponding":false},{"id":228166,"name":"Lauren A. Byers","orcid":"0000-0002-0780-2677","position":6,"is_corresponding":false},{"id":1574163,"name":"Frank Fossella","orcid":null,"position":7,"is_corresponding":false},{"id":228170,"name":"Don L. Gibbons","orcid":"0000-0003-2362-3094","position":8,"is_corresponding":false},{"id":229781,"name":"Jonathan M. Kurie","orcid":null,"position":9,"is_corresponding":false},{"id":18420,"name":"Charles Lu","orcid":"0000-0003-3450-1682","position":10,"is_corresponding":false},{"id":58539,"name":"Ferdinandos Skoulidis","orcid":"0000-0002-4676-4503","position":11,"is_corresponding":false},{"id":236018,"name":"Joe Y. Chang","orcid":"0000-0002-8435-2083","position":12,"is_corresponding":false},{"id":308376,"name":"Zhongxing Liao","orcid":"0000-0002-2224-9478","position":13,"is_corresponding":false},{"id":332026,"name":"Daniel R. Gomez","orcid":"0009-0003-8617-3868","position":14,"is_corresponding":false},{"id":1574164,"name":"Michael O'Reilly","orcid":null,"position":15,"is_corresponding":false},{"id":227923,"name":"John V. Heymach","orcid":"0000-0001-9068-8942","position":16,"is_corresponding":false},{"id":70224,"name":"Anne S. Tsao","orcid":"0000-0003-0505-6639","position":17,"is_corresponding":false},{"id":236019,"name":"Steven H. Lin","orcid":"0000-0003-4411-0634","position":18,"is_corresponding":false},{"id":873744,"name":"Yufei Liu","orcid":"0000-0003-2988-8843","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial","abstract":"<h4>Introduction</h4>The phase II DETERRED trial assessed the safety and efficacy of consolidation and concurrent immunotherapy with chemoradiation in unresectable locally advanced non-small cell lung cancer. We present updated efficacy analysis of this trial.<h4>Methods</h4>The trial was conducted in 2 parts with patients in part 1 (n = 10) receiving chemoradiation with consolidation atezolizumab, while patients in part 2 (n = 30) received concurrent and consolidation atezolizumab. Progression-free survival (PFS), time to second progression (PFS2), and overall survival (OS) were assessed using Kaplan-Meier analysis. Subset analyses were performed by programmed cell death ligand-1 (PD-L1) status and targetable driver oncogene mutation status.<h4>Results</h4>At a median follow-up of 39.2 months, the median PFS for part 1 was 18.9 months and 15.1 months for part 2. Median OS for part 1 was 26.5 months and was not reached for part 2. For the cohort, 3-year OS was 53.8%, while 4-year OS was 47.4%. Patients with targetable driver oncogene mutations had a median PFS of 9.4 months and OS of not reached compared to 16.6 months (HR: 3.49, p = 0.02) and 26.9 months (HR: 0.40, p = 0.12) respectively compared to those without targetable driver oncogene mutations. Patients with PD-L1 < 1% had median PFS of 11.0 months and OS of 26.5 months compared to 27.4 months (HR: 2.01, p = 0.10) and not reached (HR: 1.49, p = 0.41) respectively for those with PD-L1 ≥ 1%.<h4>Conclusions</h4>In the DETERRED trial, chemoradiation with concurrent and/or consolidative atezolizumab led to comparable efficacy as consolidative durvalumab in the PACIFIC trial. The presence of targetable driver oncogene mutations led to worse PFS, while PD-L1 < 1% trended to worse PFS.","is_dataset_classified":null,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36371941","pmcid":null,"openalex_id":"https://openalex.org/W4307814184","authors":[],"funders":[{"funder_name":"Genentech","grant_id":"","title":null}],"total_grants":1,"fwci":2.871,"citation_percentile":0.9290491,"influential_citations":0,"citation_trend":[{"year":2023,"count":4},{"year":2024,"count":12},{"year":2025,"count":12},{"year":2026,"count":5}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0169500222006663?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0169500222006663?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.lungcan.2022.10.006","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36371941","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","Humans","Carcinoma, Non-Small-Cell Lung","B7-H1 Antigen","Lung Neoplasms","Immunotherapy","Chemoradiotherapy"],"mesh_terms":["Carcinoma, Non-Small-Cell Lung","Humans","Immunotherapy","Lung Neoplasms","Chemoradiotherapy","B7-H1 Antigen"],"keywords":["Atezolizumab","Medicine","Oncology","Internal medicine","Phases of clinical research","Intensive care medicine","Clinical trial","Cancer","Pembrolizumab","Radiation","Immunotherapy","Non-small cell lung cancer","Targeted Therapy","Driver Mutations"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T21:01:33.959427Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}